Guidoni Camilo Molino, Camargo Helen Palmira Miranda, Obreli-Neto Paulo Roque, Girotto Edmarlon, Pereira Leonardo Regis Leira
State University of Londrina, Londrina, PR, Brazil.
Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, College of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Avenue of Café, Ribeirao Preto, SP, 14040-90, Brazil.
Int J Clin Pharm. 2016 Oct;38(5):1048-51. doi: 10.1007/s11096-016-0336-z. Epub 2016 Jun 30.
Background Drug-drug interactions in patients taking warfarin may contribute to a higher risk of adverse events. Objective To identify and evaluate the prevalence and characteristics of potential DDIs with warfarin. Methods A cross-sectional study was performed in a Brazilian tertiary hospital. The electronic prescriptions of the patients receiving warfarin between January 2004 and December 2010 were analyzed. Socio-demographic, clinical, and therapeutic variables were collected. Warfarin drug-drug interactions were classified as either risk A, B, C, D, or X according to the Lexi-Interact™ Online database. Results A total of 3048 patients were identified who were prescribed warfarin. Of the 154,161 total drug prescriptions issued, 42,120 (27.3 %) were for warfarin. Evaluation of the prescriptions showed that 63.1 and 0.1 % of patients received concomitant drugs classified as having class D or X risk. It was found that 20,539 (48.7 %) prescriptions had at least one drug with a D or X risk. Patients were prescribed an average of 1.4 (±0.4) concomitant medications with a class D or X warfarin-DDI risk, the most frequent being acetylsalicylic acid and amiodarone. Conclusion The results demonstrate a high prevalence of concomitant drug prescriptions with the potential for clinically relevant DDIs with warfarin, the most frequent being acetylsalicylic acid and amiodarone.
服用华法林的患者发生药物相互作用可能会导致更高的不良事件风险。目的:识别并评估与华法林潜在药物相互作用(DDIs)的发生率及特征。方法:在巴西一家三级医院开展了一项横断面研究。分析了2004年1月至2010年12月期间接受华法林治疗患者的电子处方。收集了社会人口统计学、临床和治疗变量。根据Lexi-Interact™在线数据库,将华法林药物相互作用分为A、B、C、D或X类风险。结果:共识别出3048例开具了华法林的患者。在总共开出的154161份药物处方中,42120份(27.3%)是华法林处方。对处方的评估显示,63.1%和0.1%的患者接受了分类为具有D类或X类风险的伴随药物。发现20539份(48.7%)处方至少有一种具有D类或X类风险的药物。患者平均开具了1.4(±0.4)种具有D类或X类华法林-DDI风险的伴随药物,最常见的是乙酰水杨酸和胺碘酮。结论:结果表明,与华法林存在潜在临床相关药物相互作用的伴随药物处方发生率很高,最常见的是乙酰水杨酸和胺碘酮。